225 related articles for article (PubMed ID: 24418752)
21. Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors.
Wolf T; Findhammer S; Nolte B; Helm EB; Brodt HR
Eur J Med Res; 2003 Jan; 8(1):17-24. PubMed ID: 12578750
[TBL] [Abstract][Full Text] [Related]
22. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.
Taura M; Kariya R; Kudo E; Goto H; Iwawaki T; Amano M; Suico MA; Kai H; Mitsuya H; Okada S
Free Radic Biol Med; 2013 Dec; 65():778-788. PubMed ID: 23973637
[TBL] [Abstract][Full Text] [Related]
23. Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.
Matondo M; Bousquet-Dubouch MP; Gallay N; Uttenweiler-Joseph S; Recher C; Payrastre B; Manenti S; Monsarrat B; Burlet-Schiltz O
Leuk Res; 2010 Apr; 34(4):498-506. PubMed ID: 19811823
[TBL] [Abstract][Full Text] [Related]
24. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
Hampson L; Kitchener HC; Hampson IN
Antivir Ther; 2006; 11(6):813-25. PubMed ID: 17310826
[TBL] [Abstract][Full Text] [Related]
25. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.
Gupta AK; Cerniglia GJ; Mick R; McKenna WG; Muschel RJ
Cancer Res; 2005 Sep; 65(18):8256-65. PubMed ID: 16166302
[TBL] [Abstract][Full Text] [Related]
26. The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.
Lan X; Kiyota T; Hanamsagar R; Huang Y; Andrews S; Peng H; Zheng JC; Swindells S; Carlson GA; Ikezu T
J Neuroimmune Pharmacol; 2012 Jun; 7(2):412-23. PubMed ID: 21826404
[TBL] [Abstract][Full Text] [Related]
27. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
Zhang L; Gorset W; Washington CB; Blaschke TF; Kroetz DL; Giacomini KM
Drug Metab Dispos; 2000 Mar; 28(3):329-34. PubMed ID: 10681378
[TBL] [Abstract][Full Text] [Related]
28. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response.
Gupta AK; Li B; Cerniglia GJ; Ahmed MS; Hahn SM; Maity A
Neoplasia; 2007 Apr; 9(4):271-8. PubMed ID: 17460771
[TBL] [Abstract][Full Text] [Related]
29. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
30. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
31. HIV protease inhibitors enhance the efficacy of irradiation.
Cuneo KC; Tu T; Geng L; Fu A; Hallahan DE; Willey CD
Cancer Res; 2007 May; 67(10):4886-93. PubMed ID: 17510418
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis.
Gaedicke S; Firat-Geier E; Constantiniu O; Lucchiari-Hartz M; Freudenberg M; Galanos C; Niedermann G
Cancer Res; 2002 Dec; 62(23):6901-8. PubMed ID: 12460905
[TBL] [Abstract][Full Text] [Related]
33. Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir.
Grigorian A; Hurford R; Chao Y; Patrick C; Langford TD
BMC Neurosci; 2008 Feb; 9():27. PubMed ID: 18302767
[TBL] [Abstract][Full Text] [Related]
34. Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells.
Hamel FG; Fawcett J; Tsui BT; Bennett RG; Duckworth WC
Diabetes Obes Metab; 2006 Nov; 8(6):661-8. PubMed ID: 17026490
[TBL] [Abstract][Full Text] [Related]
35. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
Sato A; Asano T; Ito K; Asano T
Urology; 2012 Apr; 79(4):966.e13-21. PubMed ID: 22296623
[TBL] [Abstract][Full Text] [Related]
36. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
[TBL] [Abstract][Full Text] [Related]
37. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
[TBL] [Abstract][Full Text] [Related]
38. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
[TBL] [Abstract][Full Text] [Related]
39. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
[TBL] [Abstract][Full Text] [Related]
40. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
